Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Thomas Smith

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.

Investors Business Daily

What caused South Korea’s largest ever wildfires?

After a week, efforts still continue to contain a fire that killed at least 28 people and destroyed tens of thousands of hectares of land

The Independent UK

Brickbats: March 2025

News of politicians, police, and bureaucrats behaving badly from around the world.

Reason

From analysis to the latest developments in health,
read the most diverse news in one place.

Brickbat: Following Too Closely

Former U.S. Capitol Police officer Thomas Smith was sentenced to 21 months in prison after pleading guilty to deprivation of… The post Brickbat: Following Too Closely appeared first on Reason.com.

Reason

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Investors Business Daily

Can This Growth Stock Deliver 135% Upside in 2025?

Positive clinical trial results have sparked hope for this biotech.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Investors Business Daily

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Investors Business Daily

A Complete Timeline of Lawsuits and Allegations Brought Against ‘Love Is Blind’

Netflix’s reality series has faced several accusations of labor violations and neglect towards cast members’ mental health and safety.

Marie Claire

Celldex Stock Rockets 28% On A Promising New Hives Treatment

Celldex unveiled promising results from a chronic hives treatment on Monday, and the biotech stock hit its highest point since 2021.

Investors Business Daily

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Investors Business Daily

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering

KYMR stock rocketed and then toppled Friday after Kymera outlined its newest immune disease drugs and tacked on a $275 million offering.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Love Is Blind contestant accuses Netflix of matching her with ‘walking red flag’ fiancé

Renee Poche has accused Netflix and production company Delirium TV for allegedly ‘forcing’ her to be in a relationship with ‘walking red flag’ fiancé Carter Wall

Investors Business Daily

Why CymaBay Morphed From Dollar Stock To Biotech Rocket

CymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run.

Investors Business Daily

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug

Argenx stock plummeted Tuesday after the company's drug unexpectedly failed to help patients with a rare blood disorder.

Investors Business Daily

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi

Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

SEC says SafeMoon executives withdrew $200 million from crypto project to spend on McLarens and luxury homes

SafeMoon reached a market cap of $5.7 billion at its peak in 2021.

The Independent UK

Love is Blind contestant sues for sexual assault during filming of show

In the lawsuit the contestant claims she was “incessantly groped” - allegations that have been denied by the person being accussed

Roll Call

Former Capitol Police officer pleads guilty in 2020 cruiser crash with motorcyclist - Roll Call

A former Capitol Police officer pleaded guilty Wednesday to a charge that stems from a 2020 crash in Georgetown with a police cruiser.

Investors Business Daily

Why Top-Notch MoonLake Surged 11% And Almost Broke Out

MoonLake beat Wall Street's expectations in an update for its skin-disease treatment. MLTX stock surged near a buy point.

The Independent UK

Love is Blind contestant sues for sexual assault during filming of show

In the lawsuit the contestant claims she was “incessantly groped” - allegations that have been denied by the person being accussed

Pedestrian.tv

Love Is Blind Producers Sued By Ex-Contestant For Alleged Sexual Assault & False Imprisonment

The contestant claims she raised her concerns with producers but they were allegedly "swept aside".

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.